Clinical Trial Details
| Trial ID: | L3942 |
| Source ID: | NCT05110846 |
| Associated Drug: | Placebo |
| Title: | A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Obesity|Type2 Diabetes |
| Interventions: | DRUG: Placebo|DRUG: CT-868 |
| Outcome Measures: | Primary: Change in hemoglobin A1c (HbA1c), Baseline up to 12 and 26 weeks | Secondary: Change in mean body weight, Baseline up to 12 and 26 weeks|Fasting plasma glucose, Baseline up to 12 and 26 weeks |
| Sponsor/Collaborators: | Sponsor: Carmot Therapeutics, Inc. |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 96 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT |
| Start Date: | 2022-02-22 |
| Completion Date: | 2023-03 |
| Results First Posted: | |
| Last Update Posted: | 2022-07-26 |
| Locations: | Carmot Clinical Center US01, Los Angeles, California, 90057, United States|Carmot Clinical Center MX04, Guadalajara, Jalisco, Mexico|Carmot Clinical Center MX01, Monterrey, Nuevo Leon, Mexico|Carmot Clinical Center MX02, Monterrey, Nuevo Leon, Mexico|Carmot Clinical Center MX05, Mérida, Yucatan, Mexico|Carmot Clinical Center MX03, Mexico City, Mexico |
| URL: | https://clinicaltrials.gov/show/NCT05110846 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|